UAE

The United Arab Emirates regulates health products primarily through the Ministry of Health and Prevention (MOHAP) at the federal level, alongside emirate-level authorities such as the Dubai Health Authority (DHA) and the Abu Dhabi Department of Health (DoH). The core legislative framework is anchored in Federal Law No. 4 of 1983 concerning the Pharmaceutical Profession and Institutions, supplemented by Cabinet Resolutions and ministerial decisions covering medical devices, diagnostics, and digital health tools. All health products intended for the UAE market must obtain registration or approval from the relevant authority before importation, marketing, or distribution. The regulatory process typically involves product classification, dossier submission, technical review, and issuance of a registration certificate or marketing authorization, with renewal requirements generally every three to five years depending on product category.

Submission requirements vary by product type but generally mandate appointment of a locally registered marketing authorization holder or licensed import agent to act as the official local representative. For pharmaceuticals, MOHAP follows Common Technical Document (CTD) format aligned with ICH guidelines, and it grants recognition to approvals from stringent reference authorities including the US FDA, EMA, Health Canada, and others, which can accelerate review timelines. Medical devices are classified across four risk tiers, broadly consistent with IMDRF principles, and registration through the MOHAP online portal (Sheryan system for devices and THIQAH for pharmaceuticals) is mandatory. The UAE has pursued significant regulatory modernization in recent years, including the launch of the Emirates Health Services (EHS) entity, expanded use of digital submission platforms, adoption of mutual recognition pathways for GCC-registered products through the Gulf Central Committee for Drug Registration (GCC-DR), and ongoing harmonization efforts with international standards to reduce duplication and shorten approval timelines.

Public sector procurement in the UAE operates across both federal and emirate levels, reflecting the country's federal structure. At the federal level, MOHAP and Emirates Health Services (EHS) manage procurement for federal health facilities, with tenders governed by Federal Decree-Law No. 26 of 2021 on Public Procurement and Cabinet decisions issued thereunder. Emirate-level authorities, notably the DHA in Dubai and the DoH in Abu Dhabi, operate semi-independent procurement systems for their respective facility networks, including public hospitals and primary care centers. Abu Dhabi's Health Services Company (SEHA) functions as the primary public hospital operator in that emirate and issues its own tenders. Centralized frameworks and annual or multi-year supply agreements are common for high-volume pharmaceuticals and consumables, with price registration and tender listing prerequisites often required before a product can be included in a public formulary. The UAE government prioritizes price transparency, local value addition, and quality compliance as key evaluation criteria in public tender awards.

The private healthcare sector in the UAE is substantial and growing, particularly in Dubai and Abu Dhabi, where mandatory health insurance requirements have expanded market access across hospital groups, pharmacy chains, and diagnostic networks. Private procurement occurs through direct purchasing agreements, group purchasing organizations, and distribution partnerships, with registered products able to transact commercially once regulatory approvals are in place. Donor-funded procurement channels such as UNICEF, the Global Fund, USAID, or Gavi are not significant pathways in the UAE given its high-income status; however, the UAE actively participates as a donor in these mechanisms and may procure health products for humanitarian or foreign aid programs through these channels. The UAE has introduced local manufacturing preference policies, including industrial incentive schemes under the Make in UAE and Operation 300bn industrial strategy, offering advantages to manufacturers with in-country production or technology transfer commitments, and free zone facilities in areas such as Dubai Healthcare City provide favorable environments for health sector manufacturing and distribution investments.